ArticleClinical and translational allergy2026
Long-Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundDupilumab-associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab-treated atopic dermatitis (AD) patients. We investigated the effect of long-term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins.
methodsThis prospective study included moderate-to-severe AD patients at the University Medical Center Utrecht, the Netherlands. Patients initiating dupilumab between February 2020-October 2022 were eligible to participate in scheduled ophthalmological examinations alongside routine dermatological examinations at baseline, week 28, and last follow-up (≥ 2 years). OSD severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score, with DAOSD defined as a ≥ 3-point increase from baseline. Conjunctival GC quantity and function were assessed with impression cytology. Dupilumab levels and proteins were measured in tear fluid.
resultsForty-four patients were included. OSD was present in 90.9% (n = 40/44) of patients at all visits. DAOSD occurred in 22.7% (n = 10/44) of patients; 40.0% (n = 4/10) persisted or newly developed at last follow-up. Tear break-up time decreased while tear production increased. Tear fluid dupilumab levels and AD-related inflammatory proteins decreased over time. Conjunctival GCs decreased at last follow-up compared to baseline. Mucin5AC (MUC5AC) production in CK19-CD45-MUC5AC + cells decreased at week 28 and remained stable at last follow-up.
conclusionOSD remained common during long-term dupilumab treatment in AD patients. Some patients developed worsening of OSD compatible with DAOSD, including delayed onset, highlighting the need for continued awareness of ocular side effects among clinicians. Reduced MUC5AC production and declining AD-related inflammatory proteins in tear fluid suggest changes in conjunctival homeostasis and ocular inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.